|New HIV Treatment
Dec 7, 2002
What does it mean now for new potential therapies now that Gilead Scienes is purchasing Triangle Pharmaceuticals? Are there going to be more options for HIV treatment?
| Response from Dr. Wohl
Well, this long anticipated acquisition by Gilead, the maker of tenofovir, of Triangle, a smaller company that produces FTC (a 3TC like drug), will almost certainly result in the development of a co-formulation of tenofovir and FTC. This would be a once daily pill containing these 2 medications and would be a clear alternative to Combivir (AZT + 3TC).
In addition, both companies have an interest in hepatits B therapies (tenofovir and FTC are active against hep B).
I think this is a positive move and look forward to seeing what Gilead will do. DW
Get Email Notifications When This Forum Updates or Subscribe With RSS
This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.
Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.